SBF2 and glioblastoma: Exosomal SBF2-AS1 levels in human serum may function as a potential diagnostic biomarker in GBM patients, optimizing the clinical benefits of TMZ therapy and have important significance in the development of treatment strategies for TMZ-resistant GBM patients.